GEN1042

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

20 competitors in Malignant Solid Tumor

#DrugCompanyPhaseTrials

1

Kisqali

Novartis

Phase 2

12

Cabometyx

Bristol-Myers Squibb

Phase 2

13

Alecensa

Roche

Phase 2

14

Mekinist

Novartis

Phase 2

15

Tafinlar

Novartis

Phase 2

16

Stivarga

Bayer

Phase 2

17

Ayvakit

BBlueprint Medicines

Phase 2

18

Keytruda

Merck & Co.

Phase 1

39

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

210

Paraplatin

AAvyxa

Phase 1

2Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Malignant Solid Tumor2 trials

A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors

Active, not recruiting·Genmab·Phase 1·NCT06057038·8 enrolled

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

Active, not recruiting·Genmab·Preclinical·NCT04083599·350 enrolled

Tumor1 trial

A Phase 1 Dose Finding and Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Clinical Activity of Immunoradiotherapy Combinations as a Treatment Option in Subjects With Metastatic Solid Tumors

Terminated·Genmab·Preclinical·NCT05491317·13 enrolled

Details

Drug Info

Related News